1402607-44-6

Basic information

• Product Name: 5,6-dihydroxy-2-(4-hydroxyphenyl)-7-(methoxymethoxy)-4H-chromen-4-one
• Synonyms: 5,6-dihydroxy-2-(4-hydroxyphenyl)-7-(methoxymethoxy)-4H-chromen-4-one
• CAS NO: 1402607-44-6
• Molecular Weight: 330.294
• Mol File: 1402607-44-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5,6-dihydroxy-2-(4-hydroxyphenyl)-7-(methoxymethoxy)-4H-chromen-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-dihydroxy-2-(4-hydroxyphenyl)-7-(methoxymethoxy)-4H-chromen-4-one(1402607-44-6)
• EPA Substance Registry System: 5,6-dihydroxy-2-(4-hydroxyphenyl)-7-(methoxymethoxy)-4H-chromen-4-one(1402607-44-6)

Safety Data

• Hazardous Substances Data: 1402607-44-6(Hazardous Substances Data)

Upstream product

• 529-53-3 scutellarein 
• 107-30-2 chloromethyl methyl ether 
• 27740-01-8 scutellarin 

Relevant articles and documents

Efficient synthesis of 6-o-methyl-scutellarein from scutellarin via selective methylation

Scutellarin (1) possesses distinguished efficacy in the clinical therapy of cerebral infarction, coronary heart disease, and angina pectoris. Scutellarin (1) is readily converted in vivo, therefore, synthetic methods for the construction of its metabolite

Design, Synthesis, and Biological Evaluation of Scutellarein Derivatives Based on Scutellarin Metabolic Mechanism in Vivo

Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. Their thrombin inhibition activities were tested through the analyzation of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB). The antioxidant activities of these target products were assessed by 1,1-diphenyl-2-picrylhydrazyl radical (DPPH) assay and the ability to protect PC12 cells against H2O2-induced cytotoxicity, and their solubilities were evaluated by ultraviolet (UV) spectrophotometer. The results showed that the two isopropyl groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment. Three series of scutellarein derivatives have been designed and synthesized based on metabolic mechanism of scutellarin (1) in vivo. The results of the biological evaluation showed that the two isopropyl groups substituted derivative (18c) demonstrated stronger anticoagulant activity, better water solubility, and good antioxidant activity compared with scutellarein (2), which warrants further development of 18c as a promising agent for ischemic cerebrovascular disease treatment.